GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (FRA:RTI) » Definitions » Total Operating Expense

Revance Therapeutics (FRA:RTI) Total Operating Expense : €346.1 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Revance Therapeutics Total Operating Expense?

Revance Therapeutics's Total Operating Expense for the three months ended in Mar. 2024 was €77.1 Mil. Revance Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was €346.1 Mil.

Revance Therapeutics Total Operating Expense Historical Data

The historical data trend for Revance Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics Total Operating Expense Chart

Revance Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 148.39 233.22 291.22 333.30 350.31

Revance Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74.72 94.45 77.53 96.98 77.14

Revance Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €346.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revance Therapeutics Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Revance Therapeutics (FRA:RTI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (FRA:RTI) » Definitions » Total Operating Expense
Comparable Companies
PHVS NVAX SLNO COGT AKRO INBX OLMA RGNX ADPT MDXG OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
RVNC:USA RTI:Germany
Address
1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203
Website
https://www.revance.com
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Revance Therapeutics (FRA:RTI) Headlines

No Headlines